Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MMED files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMiniMed reports record $3.1B revenue, FDA clears two new products, guides 10% FY27 growth
Filed June 3, 2026 · Period ending June 3, 2026 · ~1 min read
Key Changes
-
high
Full-year revenue hit record $3.1B (up 14.2% reported, 8.0% organic), first time crossing $3B milestone; international sales drove growth at 20.6% reported.
Exhibit 99.1 view on EDGAR → -
high
FDA cleared MiniMed Flex insulin pump and MiniMed Go Smart MDI system; Flex pre-orders started this week with shipping later this month, Go launched last week.
Exhibit 99.1 view on EDGAR → -
high
FY2027 guidance: ~10% organic revenue growth (includes 1.0-1.5% benefit from extra week) and ~16% adjusted EBITDA margin.
Exhibit 99.1 view on EDGAR → -
high
Net loss widened to $331M for FY2026 from $213M prior year ($1.29 loss per share vs. $0.83); Q4 loss $183M vs. $172M prior year.
Exhibit 99.1 view on EDGAR → -
medium
Extended partnership with Abbott for dual glucose-ketone sensors integrating exclusively with MiniMed smart dosing systems.
Exhibit 99.1 view on EDGAR →
Summary
MiniMed reported strong top-line momentum for fiscal 2026, crossing $3 billion in annual revenue for the first time with 14.2% reported growth. International markets led the expansion at 20.6%, driven by Simplera capacity increases, while U.S. sales grew a modest 1.5%. The company ended the year with approximately 659,000 worldwide pump users.
Two FDA clearances position MiniMed for accelerated growth: the MiniMed Flex next-generation pump began pre-orders this week with shipping expected later this month, and the MiniMed Go Smart MDI system launched last week. Management guides fiscal 2027 organic revenue growth at approximately 10% with adjusted EBITDA margin reaching 16%, signaling confidence in the new product cycle.
The widening net loss—$331 million for the full year versus $213 million prior year—reflects continued investment in product development and market expansion. Investors should monitor the commercial uptake of Flex and Go in coming quarters, as these launches underpin the company's double-digit growth outlook and path to profitability improvement.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
MiniMed posts investor presentation ahead of earnings call; no material business disclosures in this procedural 8-K.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
A slide presentation is being posted in advance of the earnings call discussed in the press release to the Investor Relations section of the Company's website, accessible at investors.minimed.com.
The company is posting a slide presentation to its investor relations website ahead of an earnings call. This is a routine disclosure under Regulation FD to ensure all investors have equal access to the presentation materials. The 8-K itself contains no financial results or material business updates.
Event · Exhibit 99.1
MiniMed reported Q4 and FY2026 earnings with record $3.1B annual revenue, FDA clearances for new products, and FY2027 guidance of ~10% organic growth.
Added in current filing · view on EDGAR →
Worldwide net sales of $837 million grew 15.6% as reported and 8.7% organic
MiniMed reported fourth quarter fiscal 2026 net sales of $837 million, representing 15.6% reported growth and 8.7% organic growth year-over-year. International sales of $599 million grew 22.4% as reported and 12.2% organic, driven by Simplera capacity expansion. U.S. sales of $238 million grew 15.6% as reported and organic, with early FDA clearance of MiniMed Flex shifting some customer demand.
Added in current filing · view on EDGAR →
Worldwide net sales of $3.102 billion grew 14.2% as reported and 8.0% organic
MiniMed achieved record annual net sales of $3.102 billion for fiscal year 2026, surpassing $3 billion for the first time. This represents 14.2% reported growth and 8.0% organic growth. International net sales of $2.185 billion grew 20.6% as reported and 11.2% organic, while U.S. net sales of $917 million grew 14.2%. The company ended FY26 with worldwide pump users of approximately 659,000.
Added in current filing · view on EDGAR →
Net loss attributable to the Company $ (183) $ (172) $ (331) $ (213)
MiniMed reported a net loss attributable to the company of $183 million for Q4 2026 and $331 million for the full fiscal year 2026, compared to losses of $172 million and $213 million in the prior year periods. Basic and diluted loss per share was $0.68 for Q4 and $1.29 for the full year.
Added in current filing · view on EDGAR →
U.S. FDA clearances of MiniMed Flex™ next-generation insulin pump and MiniMed Go™ Smart MDI system
MiniMed received FDA clearances for its MiniMed Flex next-generation insulin pump and MiniMed Go Smart MDI system during fiscal 2026. The company announced that MiniMed Go was launched in the U.S. last week, MiniMed Flex pre-orders started this week with shipping expected later this month, and MiniMed 780G with Instinct will launch in Europe later this month. The company also extended its partnership with Abbott to commercialize dual glucose-ketone sensors designed to integrate exclusively with MiniMed smart dosing systems.
Event · Item 2.02 — Results of Operations and Financial Condition
MiniMed Group announced Q4 and full fiscal year 2026 financial results via press release.
Added in current filing · verify on EDGAR →
On June 3, 2026, MiniMed Group, Inc., a Delaware corporation (the "Company"), issued a press release announcing its financial results and related information for its fourth quarter and full fiscal year 2026.
The company disclosed its fourth quarter and full fiscal year 2026 financial results through a press release. The 8-K filing itself does not contain the actual financial figures or performance metrics; those details are in the attached press release exhibit.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 8, 2026 · How we verify